KRRO (Korro Bio) Marketable Securities: $52.27 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KRRO Korro Bio Inc KRRO
6 GF Score
Price $13.27
! 5 Warning Signs
View Full Analysis

What is Korro Bio Marketable Securities?

Korro Bio KRRO -1.63% 6 Marketable Securities is $52.27 Mil as of Mar. 2026. GuruFocus rates KRRO with a GF Score™ of 6/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Korro Bio's Marketable Securities for the quarter that ended in Mar. 2026 was $52.27 Mil.

Korro Bio's annual Marketable Securities increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($70.45 Mil) but then declined from Dec. 2024 ($70.45 Mil) to Dec. 2025 ($53.33 Mil).

Korro Bio  (NAS:KRRO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Korro Bio Marketable Securities Related Terms

Korro Bio Marketable Securities Historical Data

* Premium members only.

The historical data trend for Korro Bio's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Korro Bio Marketable Securities Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
35.04 18.92 0.00 70.45 53.33

Korro Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.81 62.75 68.32 53.33 52.27
KRRO
6GF Score
Korro Bio Inc KRRO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Korro Bio Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $52.27 Mil mean?
Korro Bio (KRRO) has a Marketable Securities of $52.27 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Korro Bio and its competitors.
Is Korro Bio's Marketable Securities too high?
Korro Bio's current Marketable Securities is $52.27 Mil. Overall, Korro Bio has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Korro Bio's Marketable Securities compare to LENZ and ANTX?
Korro Bio's Marketable Securities of $52.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Korro Bio and its competitors. Korro Bio's current Marketable Securities is $52.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korro Bio stock overvalued right now?
Korro Bio (KRRO) has a current Marketable Securities of $52.27 Mil. The current Marketable Securities is $52.27 Mil. Korro Bio's overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Korro Bio (KRRO), the current Marketable Securities is $52.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Korro Bio Business Description

Address 60 First Street, 2nd Floor, Suite 250, Cambridge, MA, USA, 02141
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
6GF Score

Get the complete analysis for KRRO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.27
Price